. Author manuscript; available in PMC: 2016 Nov 9.

Published in final edited form as: Osteoporos Int. 2009 Oct 3;21(7):1277–1285. doi: 10.1007/s00198-009-1077-9

Table 1.

Baseline characteristics

	Zoledronic acid (n=122)	Placebo (n=111)
Age at randomization, years	74.2±5.6	74.3±6.4
Age at time of menopause, years	48.2±5.8	46.8±5.7
Race
Caucasian	90 (73.8)	89 (80.2)
Asian	32 (26.2)	22 (19.8)
Body mass index, kg/m²	25.0±4.3	24.8±3.9
Prior bisphosphonate usage
Yes	108 (88.5)	91 (82.0)
No	14 (11.5)	19 (17.1)
Missing	0	1 (0.9)
Baseline vertebral fracture
Yes	68 (55.7)	63 (56.8)
No	54 (44.3)	48 (43.2)
Patients with three infusions	92 (75.4)	83 (74.8)
Corrected BMD, g/cm³
Lumbar spine	0.807±0.119 (n=67)	0.802±0.137 (n=68)
Femoral neck	0.565±0.081 (n=97)	0.560±0.083 (n=86)
Total hip	0.681±0.101 (n=97)	0.672±0.097 (n=86)

Data are expressed as n (%) or mean+SD